- Home
- CBFV vs CGEN Comparison
CBFV vs CGEN Comparison
Compare CBFV & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBFV | CGEN |
|---|---|---|
| Founded | 1901 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.9M | 201.8M |
| IPO Year | 2014 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CBFV | CGEN |
|---|---|---|
| Price | $40.85 | $2.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $45.00 | $4.80 |
| AVG Volume (30 Days) | 7.5K | ★ 229.9K |
| Earning Date | 10-26-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.53 | N/A |
| Revenue | ★ $43,557,000.00 | N/A |
| Revenue This Year | $15.13 | N/A |
| Revenue Next Year | $7.98 | $55.33 |
| P/E Ratio | $16.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.00 | $1.43 |
| 52 Week High | $41.31 | $3.24 |
Technical Indicators
Market Signals| Indicator | CBFV | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.65 | 49.52 |
| Support Level | $36.18 | $1.98 |
| Resistance Level | $41.31 | $2.33 |
| Average True Range (ATR) | 1.03 | 0.09 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 73.35 | 73.68 |
Price Performance
Historical ComparisonAbout CBFV CB Financial Services Inc.
CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.